ETHAN: A phase 2 study comparing different Endocrine THerapies for mAle breast canNcer

Breaking it down:

How well does male breast cancer respond to pre-operative treatment with endocrine therapy and which one is the most effective?

Eligibility Criteria:

1. Are you man recently diagnosed with breast cancer (before surgery) and 18 years or older??
2. Is your breast cancer Stage 1,2, or 3 and hormone-receptor positive and HER 2- negative?

Trial:

• Open label, Randomized, Treatment trial.

Drugs used:

• Tamoxifen (Brand name is Novadex), is currently the standard of care for men with breast cancer. It is classified as an oral Selective Estrogen Receptor Modulator (SERM) and blocks the estrogen receptors on cells.
• Anastrozole (Brand name is Arimidex), used to treat hormone-receptor positive breast cancer by lowering estrogen levels in the body. It is an oral nonsteroidal aromatase inhibitor.
• Degarelix (Brand name is Firmagon), used for gonadal suppression by lowering testosterone. It is administered by a subcutaneous injection under the skin.
• Abemaciclib (Brand name is Verzenio), an oral targeted therapy used to treat hormone positive and HER2- negative breast cancer. It is classified as a cyclin-dependent kinase (CDK) 4/6 inhibitor. It is currently prescribed for high-risk for reoccurrence, advanced or metastatic breast cancer. It works by blocking proteins on the cancer cells, to prevent the cell cycle and will inhibit growth and spread of the cancer cells.

Locations and Contacts:

7 locations through-out the United States, including Pittsburgh.

• Carol Glock M.Ed
  Phone: 412-680-6496
• Cortney Montgomery BSN, RN, CCRP, CBCN
  Phone: 412-641-1840